NCT04771676View on ClinicalTrials.gov

Intraperitoneal Injection of Oncolytic Viruses H101 for Patients With Refractory Malignant Ascites

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 5, 2021

Primary Completion Date

January 31, 2023

Study Completion Date

January 31, 2023

Conditions
Refractory Malignant Ascites
Interventions
DRUG

Oncorine (H101)

A modified human recombinant type 5 adenovirus with genetic modifications.

Trial Locations (1)

Unknown

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT04771676 - Intraperitoneal Injection of Oncolytic Viruses H101 for Patients With Refractory Malignant Ascites | Biotech Hunter | Biotech Hunter